Systemic treatment for hepatocellular carcinoma beyond milan criteria on the waitlist:is it time for a neoadjuvant therapy?  

作　　者：Bianca Magro Michela Triolo Ciro Celsa Duilio Pagano Giuseppe Cabibbo Calogero Cammà Stefano Fagiuoli Salvatore Gruttadauria 

机构地区：[1]Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation,IRCCS-ISMETT(Istituto di Ricovero e Cura a Carattere Scientifico-Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione),UPMC(University of Pittsburgh Medical Center),Palermo 90127,Italy [2]Gastroenterology,Hepatology and Transplantation Unit,Department of Specialty and Transplant Medicine,Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII,Bergamo 24127,Italy [3]Section of Gastroenterology and Hepatology,Department of Health Promotion,Mother and Child Care,Internal Medicine and Medical Specialties,PROMISE,University of Palermo,Palermo 90127,Italy [4]Department of Surgical,Oncological,and Oral Sciences(Di.Chir.On.S.),University of Palermo,Palermo 90127,Italy [5]Gastroenterology,Department of Medicine,University of Milano Bicocca,Milan 20126,Italy [6]Department of Surgery and Medical and Surgical Specialties,University of Catania,Catania 9513,Italy

出　　处：《Hepatoma Research》2023年第1期688-692,共5页肝癌研究(英文版)

摘　　要：Dear Editor,Liver transplantation(LT)is the best option for the treatment of both cirrhosis and hepatocellular carcinoma(HCC),providing the best long-term outcomes,particularly for patients within the Milan criteria[1].Efforts have been made to expand these criteria in order to expand the offer of LT to a higher number of patients with HCC while maintaining an acceptable risk of post-LT HCC recurrence[2].

关 键 词：HEPATOCELLULAR TREATMENT LIVER 

分 类 号：R73[医药卫生—肿瘤]